Journal of Pharmacy & Pharmacognosy Research’s Post

Risk factors for oral cancer: Thematic trends and research agenda. https://ow.ly/R8C550Qx2LL #OralCancer #SystematicReview #Pharmacology #Pharmacy

Our #CancerResearch approach is driven by our deep understanding of causal human biology. Leveraging our differentiated research platforms, targeted #ProteinDegradation, #CellTherapy and radiopharmaceutical therapeutics (RPTs), we’re leading the way as we work to advance transformative new treatment options for patients. Explore our approach to cancer research: https://bit.ly/3Rb1R5C #ASCO24

Thoughts on this? >> Exelixis’ Cabometyx misses survival endpoint, but will still file in prostate cancer >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

Thoughts on this? >> FDA approves Roche's new treatment for subset of breast cancer patients >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #productmarketing #pharmaceutical

Thoughts on this? >> Exelixis’ Cabometyx misses survival endpoint, but will still file in prostate cancer >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #biotech #pharma #pharmaceutical

Body Mass Index and Survival in Advanced Biliary Tract Cancer: A Comprehensive Study BMI may not significantly impact survival in patients with advanced biliary tract cancer, according to a comprehensive study involving 360 patients receiving chemotherapy. The study found no significant association between BMI and overall survival, and this finding was validated in a nationwide database. The study suggests that BMI alone should not be used as a prognostic factor for survival in these patients, and future research should consider more detailed body composition metrics. Clinicians should focus on individualized treatment plans rather than relying solely on BMI. For more details please click the link! https://lnkd.in/dW6e_D9H #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Thoughts on this? >> Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare

Design and computational study of the thiourea–cobalt(III) complex as an anticancer candidate. https://ow.ly/cT2q50Qx36A #Pharmacy #Pharmacology #Cancer #InSilico

🚀 Reminder: Webinar on Advances in Antibody-Drug Conjugates (ADCs) - Happening Today! 🚀 Don't miss our webinar TODAY where we'll dive into the latest breakthroughs in Antibody-Drug Conjugates (ADCs), a revolutionary approach in cancer therapy. 📅 Date: Today, June 26 🌟 Register Now: https://lnkd.in/g5z9NSRC If you haven't registered yet, it's not too late! Make sure to secure your spot now! #CancerResearch #Biotechnology #AntibodyDrugConjugates #Pharmaceuticals #Webinar #HealthcareInnovation

Thoughts on this? >> Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech